The single nucleotide polymorphism (SNP) at codon 72 of the tumor suppressor gene p53 codes for either an arginine (R) or proline (P) (p53 R72P). This SNP may impact how cells respond to genotoxic insult. Studies in cell culture and in tissues from mouse models of the SNP indicate that, in response to gentoxic treatment, the two variants may differentially induce apoptosis and expression of p53 target genes. In epidemiological studies, the P variant is associated with decreased cancer survival and increased risk of side-effects from genotoxic cancer treatment. Genotoxic therapy is still the mainstay of cancer treatment, and doxorubicin and/or ionizing radiation (IR) are used in many treatment regimens. In this project I employed our mouse models of the p53 R72P polymorphism to test how this SNP modulates physiological effects of doxorubicin and IR. To test how the p53 R72P polymorphism affects doxorubicin tolerance at a physiological level and in gene expression profiles, I performed blood counts and RNA sequencing of tissues from doxorubicin treated and untreated p53 R72P mice. To test how the p53 R72P polymorphism affects IR tolerance, I performed a survival study, immunohistochemical (IHC) staining, blood counts and used quantitative PCR to analyze p53 target gene expression in IR treated and untreated p53 R72P mice. In both studies I stringently controlled for background strain, age and sex. Due to an unexpected tolerance to doxorubicin in the FVB mouse strain employed, the doxorubicin studies were inconclusive. While IR did elicit a significant response, my findings did not support a role for the p53 R72P polymorphism in modulating the adverse effect IR therapy, and indicate that personalization of these therapies based on this SNP could have limited clinical utility.
","abstract_html":"<p>The single nucleotide polymorphism (SNP) at codon 72 of the tumor suppressor gene <em>p53 </em>codes for either an arginine (R) or proline (P) (p53 R72P). This SNP may impact how cells respond to genotoxic insult. Studies in cell culture and in tissues from mouse models of the SNP indicate that, in response to gentoxic treatment, the two variants may differentially induce apoptosis and expression of p53 target genes. In epidemiological studies, the P variant is associated with decreased cancer survival and increased risk of side-effects from genotoxic cancer treatment. Genotoxic therapy is still the mainstay of cancer treatment, and doxorubicin and/or ionizing radiation (IR) are used in many treatment regimens. In this project I employed our mouse models of the p53 R72P polymorphism to test how this SNP modulates physiological effects of doxorubicin and IR. To test how the p53 R72P polymorphism affects doxorubicin tolerance at a physiological level and in gene expression profiles, I performed blood counts and RNA sequencing of tissues from doxorubicin treated and untreated p53 R72P mice. To test how the p53 R72P polymorphism affects IR tolerance, I performed a survival study, immunohistochemical (IHC) staining, blood counts and used quantitative PCR to analyze p53 target gene expression in IR treated and untreated p53 R72P mice. In both studies I stringently controlled for background strain, age and sex. Due to an unexpected tolerance to doxorubicin in the FVB mouse strain employed, the doxorubicin studies were inconclusive. While IR did elicit a significant response, my findings did not support a role for the p53 R72P polymorphism in modulating the adverse effect IR therapy, and indicate that personalization of these therapies based on this SNP could have limited clinical utility.</p>","abstract_has_math":false,"creators":["Dominguez, Emily"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation (PhD)","degree_discipline":null,"degree_department":null,"school":null,"contributors":["David Johnson, PhD","Mark Bedford, PhD","Rick FInch, PhD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-12-01T08:00:00Z","date_published":"2016-12-01T08:00:00Z","updated_at":"2026-07-24T05:49:54Z","subjects":["mouse models","p53","single nucleotide polymorphism","genotoxins","Cell Biology","Genetics and Genomics","Medicine and Health Sciences","Other Pharmacology, Toxicology and Environmental Health"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.library.tmc.edu/utgsbs_dissertations/720","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["David Johnson, PhD","Mark Bedford, PhD","Rick FInch, PhD"]},{"key":"dc:creator","label":"Author","values":["Dominguez, Emily"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2016-12-13T08:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation (PhD)"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["mouse models","p53","single nucleotide polymorphism","genotoxins","Cell Biology","Genetics and Genomics","Medicine and Health Sciences","Other Pharmacology, Toxicology and Environmental Health"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/720"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The single nucleotide polymorphism (SNP) at codon 72 of the tumor suppressor gene p53 codes for either an arginine (R) or proline (P) (p53 R72P). This SNP may impact how cells respond to genotoxic insult. Studies in cell culture and in tissues from mouse models of the SNP indicate that, in response to gentoxic treatment, the two variants may differentially induce apoptosis and expression of p53 target genes. In epidemiological studies, the P variant is associated with decreased cancer survival and increased risk of side-effects from genotoxic cancer treatment. Genotoxic therapy is still the mainstay of cancer treatment, and doxorubicin and/or ionizing radiation (IR) are used in many treatment regimens. In this project I employed our mouse models of the p53 R72P polymorphism to test how this SNP modulates physiological effects of doxorubicin and IR. To test how the p53 R72P polymorphism affects doxorubicin tolerance at a physiological level and in gene expression profiles, I performed blood counts and RNA sequencing of tissues from doxorubicin treated and untreated p53 R72P mice. To test how the p53 R72P polymorphism affects IR tolerance, I performed a survival study, immunohistochemical (IHC) staining, blood counts and used quantitative PCR to analyze p53 target gene expression in IR treated and untreated p53 R72P mice. In both studies I stringently controlled for background strain, age and sex. Due to an unexpected tolerance to doxorubicin in the FVB mouse strain employed, the doxorubicin studies were inconclusive. While IR did elicit a significant response, my findings did not support a role for the p53 R72P polymorphism in modulating the adverse effect IR therapy, and indicate that personalization of these therapies based on this SNP could have limited clinical utility.
"]},{"key":"dc:title","label":"Title","values":["Using Mouse Models to Define How The P53 R72P Polymorphism Impacts The Adverse Effects of Doxorubicin and Ionizing Radiation"]}]}],"canonical_facts":{"dc:contributor":["David Johnson, PhD","Mark Bedford, PhD","Rick FInch, PhD"],"dc:creator":["Dominguez, Emily"],"dc:date.available":["2016-12-13T08:00:00Z"],"dc:description.abstract":["The single nucleotide polymorphism (SNP) at codon 72 of the tumor suppressor gene p53 codes for either an arginine (R) or proline (P) (p53 R72P). This SNP may impact how cells respond to genotoxic insult. Studies in cell culture and in tissues from mouse models of the SNP indicate that, in response to gentoxic treatment, the two variants may differentially induce apoptosis and expression of p53 target genes. In epidemiological studies, the P variant is associated with decreased cancer survival and increased risk of side-effects from genotoxic cancer treatment. Genotoxic therapy is still the mainstay of cancer treatment, and doxorubicin and/or ionizing radiation (IR) are used in many treatment regimens. In this project I employed our mouse models of the p53 R72P polymorphism to test how this SNP modulates physiological effects of doxorubicin and IR. To test how the p53 R72P polymorphism affects doxorubicin tolerance at a physiological level and in gene expression profiles, I performed blood counts and RNA sequencing of tissues from doxorubicin treated and untreated p53 R72P mice. To test how the p53 R72P polymorphism affects IR tolerance, I performed a survival study, immunohistochemical (IHC) staining, blood counts and used quantitative PCR to analyze p53 target gene expression in IR treated and untreated p53 R72P mice. In both studies I stringently controlled for background strain, age and sex. Due to an unexpected tolerance to doxorubicin in the FVB mouse strain employed, the doxorubicin studies were inconclusive. While IR did elicit a significant response, my findings did not support a role for the p53 R72P polymorphism in modulating the adverse effect IR therapy, and indicate that personalization of these therapies based on this SNP could have limited clinical utility.
"],"dc:identifier":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/720"],"dc:subject":["mouse models","p53","single nucleotide polymorphism","genotoxins","Cell Biology","Genetics and Genomics","Medicine and Health Sciences","Other Pharmacology, Toxicology and Environmental Health"],"dc:title":["Using Mouse Models to Define How The P53 R72P Polymorphism Impacts The Adverse Effects of Doxorubicin and Ionizing Radiation"],"thesis:degree_level":["Dissertation (PhD)"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T05:49:54Z"}